ArticleFrontiers in molecular biosciences2025
Metabolic reprogramming signature predicts prognosis and immune landscape in small cell lung cancer: MOCS2 validation and implications for personalized therapy.
Junyan Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.